Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations

Verfasser / Beitragende:
[Toshihiko Iuchi, Masato Shingyoji, Meiji Itakura, Sana Yokoi, Yasumitsu Moriya, Hajime Tamura, Yasushi Yoshida, Hironori Ashinuma, Koichiro Kawasaki, Yuzo Hasegawa, Tsukasa Sakaida, Toshihiko Iizasa]
Ort, Verlag, Jahr:
2015
Enthalten in:
International Journal of Clinical Oncology, 20/4(2015-08-01), 674-679
Format:
Artikel (online)
ID: 605491305
LEADER caa a22 4500
001 605491305
003 CHVBK
005 20210128100509.0
007 cr unu---uuuuu
008 210128e20150801xx s 000 0 eng
024 7 0 |a 10.1007/s10147-014-0760-9  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s10147-014-0760-9 
245 0 0 |a Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations  |h [Elektronische Daten]  |c [Toshihiko Iuchi, Masato Shingyoji, Meiji Itakura, Sana Yokoi, Yasumitsu Moriya, Hajime Tamura, Yasushi Yoshida, Hironori Ashinuma, Koichiro Kawasaki, Yuzo Hasegawa, Tsukasa Sakaida, Toshihiko Iizasa] 
520 3 |a Background: The brain is a frequent site of metastases from non-small-cell lung cancer (NSCLC). We analyzed the frequency of brain metastases (BMs) from NSCLC in the era of magnetic resonance images, and evaluated the correlation between epidermal growth factor receptor (EGFR) mutations and BMs among East Asian patients. Methods: Frequency, number, and size of BMs, and survival of 1,127 NSCLC patients were retrospectively reviewed. Mutation status of EGFR was evaluated in all cases, and its association with BMs was statistically evaluated. Results: EGFR mutations were found for 331 cases (29.4%). BM was the cause of primary symptoms for 52 patients (4.6%), and found before initiation of treatment for 102 other patients (9.1%); In addition to these 154 patients, 107 patients (9.5%) developed BMs, giving a total of 261 patients (23.2%) who developed BMs from 1,127 with NSCLC. BM frequency was higher among EGFR-mutated cases (31.4%) than EGFR-wild cases (19.7%; odds ratio: 1.86; 95% confidence interval (CI) 1.39-2.49; P<0.001). BMs from EGFR-mutated NSCLC were small, but often became disseminated. EGFR mutations accounted for 39.9% of BMs, but patient survival after BMs was significantly longer for EGFR-mutated cases than for EGFR-wild cases (hazard ratio: 2.23; 95% CI 1.62-3.10; P<0.001). Conclusions: Patients with EGFR-mutated NSCLC were more likely to develop BMs, but apparently also survived longer after BMs. 
540 |a Japan Society of Clinical Oncology, 2014 
690 7 |a Non-small-cell lung cancer (NSCLC)  |2 nationallicence 
690 7 |a Epidermal growth factor receptor ( EGFR )  |2 nationallicence 
690 7 |a Brain metastasis  |2 nationallicence 
690 7 |a Epidemiology  |2 nationallicence 
690 7 |a Survival  |2 nationallicence 
700 1 |a Iuchi  |D Toshihiko  |u Division of Neurological Surgery, Chiba Cancer Center, 260-8717, Chiba, Japan  |4 aut 
700 1 |a Shingyoji  |D Masato  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
700 1 |a Itakura  |D Meiji  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
700 1 |a Yokoi  |D Sana  |u Gene Diagnosis, Chiba Cancer Center, Chiba, Japan  |4 aut 
700 1 |a Moriya  |D Yasumitsu  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
700 1 |a Tamura  |D Hajime  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
700 1 |a Yoshida  |D Yasushi  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
700 1 |a Ashinuma  |D Hironori  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
700 1 |a Kawasaki  |D Koichiro  |u Division of Neurological Surgery, Chiba Cancer Center, 260-8717, Chiba, Japan  |4 aut 
700 1 |a Hasegawa  |D Yuzo  |u Division of Neurological Surgery, Chiba Cancer Center, 260-8717, Chiba, Japan  |4 aut 
700 1 |a Sakaida  |D Tsukasa  |u Division of Neurological Surgery, Chiba Cancer Center, 260-8717, Chiba, Japan  |4 aut 
700 1 |a Iizasa  |D Toshihiko  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
773 0 |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/4(2015-08-01), 674-679  |x 1341-9625  |q 20:4<674  |1 2015  |2 20  |o 10147 
856 4 0 |u https://doi.org/10.1007/s10147-014-0760-9  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s10147-014-0760-9  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Iuchi  |D Toshihiko  |u Division of Neurological Surgery, Chiba Cancer Center, 260-8717, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Shingyoji  |D Masato  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Itakura  |D Meiji  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Yokoi  |D Sana  |u Gene Diagnosis, Chiba Cancer Center, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Moriya  |D Yasumitsu  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Tamura  |D Hajime  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Yoshida  |D Yasushi  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ashinuma  |D Hironori  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kawasaki  |D Koichiro  |u Division of Neurological Surgery, Chiba Cancer Center, 260-8717, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Hasegawa  |D Yuzo  |u Division of Neurological Surgery, Chiba Cancer Center, 260-8717, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Sakaida  |D Tsukasa  |u Division of Neurological Surgery, Chiba Cancer Center, 260-8717, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Iizasa  |D Toshihiko  |u Thoracic Disease, Chiba Cancer Center, Chiba, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/4(2015-08-01), 674-679  |x 1341-9625  |q 20:4<674  |1 2015  |2 20  |o 10147